Orion Group Interim Report January–September 2013

Orion’s net sales in January–September 2013 totalled EUR 734 million (EUR 726 million in January–
September 2012).

•  Operating profit was EUR 202 (220) million.

• Profit before taxes was EUR 200 (219) million.

• Equity ratio was 52% (59%).

• ROCE before taxes was 39% (50%).

• ROE after taxes was 41% (46%).

• Basic earnings per share were EUR 1.07 (1.17).

• Cash flow per share before financial items was EUR 0.56 (0.92).

• The outlook estimate for 2013 remains unchanged. Orion estimates that in 2013 net sales will be at similar level to 2012 and that operating profit will be slightly lower than in 2012.

• Promising results from Phase II clinical trials of ODM-201.

• Orion and Endo have terminated their collaboration agreement concerning oncology drug research, development and commercialisation. Among others, all the rights of ODM-201 revert to Orion.

• Orion and Hospira have extended their licensing agreement concerning the sedative agent Precedex® in the markets outside the Europe.

For more information, click the link below.

Orion Q3-2013

Fortum Corporation Interim Report January - September 2013

Typically weak third-quarter results further burdened by very low hydro volumes – strong cash flow

July−September 2013
• Comparable operating profit EUR 166 (223) million, -26%
• Operating profit EUR 97 (226) million, of which EUR -69 (3)   million relates to items affecting comparability
• Earnings per share EUR 0.04 (0.14), -71%, of which EUR -0.05 (0.01) per share relates to items affecting comparability
• Cash flow from operating activities totalled EUR 414 (111) million, +273%
• Nearly all-time low hydro production, 3.9 (6.3) TWh
• 2014: 65% hedged at EUR 42 per MWh; and 2015: 20% hedged at  EUR 41 per MWh
• Finalisation of the Russian investment programme postponed by some months; ready by mid-2015
• Electricity production at the Inkoo coal-fired power plant in Finland to be discontinued

 For more information, click the link below.

Fortum Corporation Q3-2013

Keep that in mind

September Dividend Income

In September, the portfolio dividend income was as follows:
PRS.OL NOK534.00
SDIV $80.10
OGZPY $108.15
GLNG $67.50
Total income was €258.02, after tax €198.41.

Kraft Foods Raises Dividend By 5%; Now Offers a 3.90% Yield (KRFT)

Late on Tuesday, October 1st 2013,  packaged foods manufacturer Kraft Foods Group Inc declared its next quarterly dividend, raising that payout to shareholders by 5%.
Kraft Foods will now pay out a quarterly dividend of 52.5 cents per share, up from its prior dividend payout of 50 cents per share. This new dividend will be paid on October 25 to shareholders of record on October 11, with an ex-dividend date of October 9.

September Transactions

On september 16th 2013 I bought 250 shares of Alerian MPL ETF (AMLP) to my portfolio at the price of €12.87 per share plus commission. That will give me about a 6.14% yield on cost. At the current dividend rate, I can expect to receive quarterly dividends of €34.35 (netto) from this purchase, which will add a total of €137.40 (netto) to my annual dividend income. My total holdings of AMLP are now 500.

On september 19th 2013 I bought 300 shares of Prosafe Se (PRS.OL) to my portfolio at the price of €6.53 per share plus commission. That should give me a 6.77% yield on cost. At the current dividend rate I can expect to recive quarterly dividends of €23.67 (netto) from this purchase, which will add a total of €94.67 (netto) to my annual dividend income. My total holdings of Prosafe SE are now 900.

August Dividend Income

In August, the portfolio dividend income was as follows:
T $54.00
SDIV $83.10
AMLP $67.25

Total income was €152.63, after tax €110.49.